Astrana Health (NASDAQ:ASTH) Trading Up 5.3% - Should You Buy?

Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) shot up 5.3% during trading on Monday . The stock traded as high as $27.19 and last traded at $26.74. 82,603 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 240,060 shares. The stock had previously closed at $25.38.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ASTH shares. Robert W. Baird lowered their price target on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday. Stifel Nicolaus decreased their price objective on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Bank of America decreased their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a report on Tuesday. Macquarie raised shares of Astrana Health to a "hold" rating in a research report on Monday, December 16th. Finally, Truist Financial reduced their target price on shares of Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Astrana Health has an average rating of "Moderate Buy" and an average target price of $56.83.

Astrana Health Stock Up 0.1 %

The company's 50-day moving average is $34.44 and its 200 day moving average is $44.05. The company has a market capitalization of $1.53 billion, a PE ratio of 20.93, a P/E/G ratio of 1.37 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.

Remove Ads

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $665.21 million for the quarter, compared to analysts' expectations of $617.24 million. As a group, analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.

Hedge Funds Weigh In On Astrana Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC bought a new position in Astrana Health during the 3rd quarter valued at about $35,000. KBC Group NV bought a new position in Astrana Health during the 3rd quarter valued at about $70,000. Pilgrim Partners Asia Pte Ltd bought a new position in Astrana Health during the 4th quarter valued at about $40,000. Quarry LP bought a new position in Astrana Health during the 3rd quarter valued at about $77,000. Finally, Quest Partners LLC bought a new position in Astrana Health during the 3rd quarter valued at about $133,000. Institutional investors own 52.77% of the company's stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.